雷傑納隆藥廠REGN
那斯達克 · USD
805.94
-4.37
(-0.54%)
盤中 09/10 03:21 (UTC+8)
09/10 03:21 (UTC+8)
雷傑納隆藥廠REGN
805.94
-4.37
(-0.54%)
財務數據
損益表
- 31.45
- 35.47
- 37.21
- 37.89
- 30.29
- 36.76
- 37.54
- 38.84
- 36.05
- 42.91
- -8.42
- 12.79
- 4.89
- 1.84
- -20.07
- 21.36
- 2.14
- 3.46
- -7.18
- 19.01
- 營業收入(億)
- 季增長率(%)
單位：美元千元
2026/Q2 | 2026/Q1 | 2025/Q4 | 2025/Q3 | 2025/Q2 | 2025/Q1 | 2024/Q4 | 2024/Q3 | 2024/Q2 | 2024/Q1 | |
營業收入淨額 | 4,290,700 | 3,605,400 | 3,884,300 | 3,754,300 | 3,675,600 | 3,028,700 | 3,789,200 | 3,720,700 | 3,547,100 | 3,145,000 |
營業成本 | 576,500 | 669,400 | 584,600 | 521,600 | 530,200 | 464,300 | 565,400 | 491,100 | 480,200 | 433,800 |
營業毛利 | 3,714,200 | 2,936,000 | 3,299,700 | 3,232,700 | 3,145,400 | 2,564,400 | 3,223,800 | 3,229,600 | 3,066,900 | 2,711,200 |
營業費用 | 2,420,700 | 2,293,100 | 2,419,800 | 2,205,900 | 2,065,900 | - | 2,233,600 | - | - | 1,959,800 |
研發費用 | 1,631,600 | 1,543,500 | 1,626,100 | 1,475,000 | 1,421,700 | 1,327,400 | 1,412,100 | 1,271,500 | 1,200,000 | 1,248,400 |
推銷及管理費用 | 662,100 | 647,700 | 775,000 | 647,800 | 634,200 | 633,000 | 807,700 | 722,400 | 773,400 | 704,300 |
非經常性項目費用 | 127,000 | 101,900 | 18,700 | 83,100 | 10,000 | 12,300 | 13,800 | 56,200 | 23,900 | 7,100 |
其他營業費用 | - | - | - | - | - | - | - | - | - | - |
營業利益 | 1,420,500 | 744,800 | 879,900 | 1,026,800 | 1,079,500 | 591,700 | 990,200 | 1,179,500 | 1,069,600 | 751,400 |
其他收入及費用 | 245,300 | 201,200 | 176,000 | 755,800 | 442,800 | 322,000 | -21,600 | 327,300 | 573,300 | -34,600 |
利息費用 | 11,000 | 12,900 | 12,200 | 19,300 | 3,600 | 8,700 | 10,500 | 13,800 | 14,800 | 16,100 |
稅前純益 | 1,527,800 | 831,200 | 1,043,700 | 1,763,300 | 1,518,700 | 905,000 | 958,100 | 1,493,000 | 1,628,100 | 700,700 |
所得稅 | 230,900 | 104,000 | 199,100 | 303,300 | 127,100 | 96,300 | 40,400 | 152,400 | 195,800 | -21,300 |
稅後純益 | 1,296,900 | 727,200 | 844,600 | 1,460,000 | 1,391,600 | 808,700 | 917,700 | 1,340,600 | 1,432,300 | 722,000 |
基本每股稅後盈餘(元) | 12.62 | 6.99 | 8.21 | 14.09 | 13.24 | 7.58 | 8.53 | 12.40 | 13.25 | 6.70 |
稀釋每股稅後盈餘(元) | 12.20 | 6.75 | 7.87 | 13.62 | 12.81 | 7.27 | 8.11 | 11.55 | 12.41 | 6.27 |
基本平均股數(千股) | 102800.00 | 104000.00 | 102900.00 | 103600.00 | 105100.00 | 106700.00 | 107600.00 | 108100.00 | 108100.00 | 107800.00 |
稀釋平均股數(千股) | 106000.00 | 107700.00 | 107500.00 | 107200.00 | 108600.00 | 111200.00 | 113800.00 | 116200.00 | 115400.00 | 115100.00 |
還原基本每股稅後盈餘(元) | 12.62 | 6.99 | 8.21 | 14.09 | 13.24 | 7.58 | 8.53 | 12.40 | 13.25 | 6.70 |
還原稀釋每股稅後盈餘(元) | 12.20 | 6.75 | 7.87 | 13.62 | 12.81 | 7.27 | 8.11 | 11.55 | 12.41 | 6.27 |
還原基本平均股數(千股) | 102,800 | 104,000 | 102,900 | 103,600 | 105,100 | 106,700 | 107,600 | 108,100 | 108,100 | 107,800 |
還原稀釋平均股數(千股) | 106,000 | 107,700 | 107,500 | 107,200 | 108,600 | 111,200 | 113,800 | 116,200 | 115,400 | 115,100 |
EBITDA(千元) | 1,662,500 | 967,300 | 1,200,900 | 1,919,300 | 1,657,400 | 1,040,600 | 1,095,000 | 1,628,500 | 1,763,600 | 830,900 |